Présentations scientifiques

Updated Results of the Phase I BALLI-01 Trial of UCART22 Process 2 (P2), an Anti-CD22 Allogeneic CAR-T-Cell Product Manufactured by Cellectis Biologics, in Patients with Relapsed or Refractory (R/R) CD22+ (B-ALL) - ASH 2023 - Présentation Poster

Télécharger le PDF

Preliminary Results of NatHaLi-01: A First-In-Human Phase I/IIa Study of UCART20x22, a Dual Allogeneic CAR-T Cell Product Targeting CD20 and CD22, in Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL) - ASH 2023 - Présentation Poster

Télécharger le PDF

TGFBR2 KO combined with activation-induced IL12 secretion synergize to optimize potency and safety of MUC1-CAR T-cells in preclinical targeting of triple-negative breast cancer - SITC - Présentation Poster

Télécharger le PDF

Comprehensive Analysis of the Editing Window of TALE Base Editors - ESGCT 2023 - Présentation Poster

Télécharger le PDF

Intronic editing enables lineage-specific expression of therapeutics relevant for HSPC gene therapy - ESGCT 2023 - Présentation Poster

Télécharger le PDF

Non-Viral DNA Delivery Coupled To TALEN Gene Editing Efficiently Correct The Sickle Cell Mutation In Long-Term HSCS - ESGCT 2023 - Présentation Poster

Télécharger le PDF

TALEN®-Edited Inducible Dual Car T-Cells Aimed at Safe and Effective Targeting Of Solid Tumors - CICON 2023 - Présentation Poster

Télécharger le PDF

Updated Results of the Phase I BALLI-01 Trial of UCART22, an Anti-CD22 Allogeneic CAR T-cell Product, in Patients with Relapsed or Refractory (R/R) CD22+ B-Cell Acute Lymphoblastic Leukemia (B-ALL) - EHA 2023 - Présentation Poster

Télécharger le PDF

UCART20x22: allogeneic dual CAR T-cells for the treatment of B-cell malignancies - ISCT 2023 - Présentation orale

Télécharger le PDF

Comprehensive Analysis of the Editing Window of TALE Base Editors - ISCT 2023 - Présentation poster

Télécharger le PDF